Healthcare Companies Worldwide

BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com

biosurfit develops innovative medical diagnostic solutions in order to improve the performance and outcomes of physicians, by providing real-time and accurate results of blood analysis. Its core product is spinit®, a user-friendly instrument that combined with a disposable disc uses one small drop of blood to give precise results within minutes for multi-parameter test panels. spinit® will soon have the potential to perform a vast majority of blood tests combining cell and immuno-based diagnostics, with integrated sample preparation into the disposable disc. biosurfit will continuously develop different tests for the spinit® platform, addressing the physicians' needs.

Blueprint Genetics is a genetic diagnostics company based in Helsinki, Seattle and Dubai. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. An important challenge for any therapeutics company using machine learning is “ground-truth data,” or information known to be true. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems. The platform then requests new experiments to improve its predictive ability, cutting through an otherwise intractable combinatorial space.

Endomag is a medical technology company devoted to improving the global standard of cancer care. Our Sentimag® probe, Magseed® marker and Magtrace® lymphatic mapping agent are already in use by many of the world’s leading physicians and cancer centres. Our goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. We’ve helped tens of thousands of women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), we continue to develop our unique clinical platform from our headquarters in Cambridge, United Kingdom.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

ExactCure provides a personalized eHealth software solution. Our VISION is to live in a world where each individual has access to a personalized medication. Our MISSION is to predict the personalized effects and interactions of drugs within the body of each individual. Problem: Inappropriate medical treatments sometimes cause illness. This “iatrogenic” side effect leads to 20,000 deaths and costs €10 billion per year to the public healthcare system in France alone. Worldwide, it probably leads to more than 1 million deaths and $1 trillion in healthcare costs. Solution: Part of the solution lies in personalized medicine. That is why ExactCure created a Digital Twin. It is a non-intrusive personalized health solution able to predict the efficacy and interactions of drugs based on the specific characteristics of each individual (gender, age, weight, etc.) in real time. This electronic support (simulation, alerts, notification) will augment and secure the therapy. Our solution comes as an App for the patient’s everyday life, and as a SaaS dashboard for the health professional.

The leading independent provider of physiotherapy and associated services in the UK - helping thousands of people to elevate their health and live active lives every day. We are a dynamic and progressive company - advancing physical therapies by making them more accessible to all, raising standards and improving methodologies. With extensive national coverage, we have over 300 highly trained Ascenti clinicians delivering upwards of 52,000 treatment sessions every month. Enabling people to make headway after illness and injury, step back in to work after accidents, or simply stay active and keep moving forward in their daily lives. As a trusted partner to more than 20 NHS CCG partners and over 400 private businesses, you can depend on us to provide safe and effective treatments that are a cut above.

Make care flows work harder than care teams with Awell Awell is a technology company for virtual-first care providers. Care teams use the Awell no-code platform to design, operate and improve care flows to automate, coordinate and standardize work. Using the Awell platform results in faster time to market, lower engineering costs and improved outcomes. 20+ healthcare organizations have realized results such as 40% reduction in length of stay, 25% reduction in emergency room admissions and near doubling of life expectancy for lung cancer patients.

Axiles Bionics is a new Brussels spin-off, from de Vrije Universiteit Brussel, developing the newest generation robotic ankle-foot prosthesis. Our mission is to improve the quality of life of amputees by bringing this newest bionic foot to the market.

For hospitals and clinics that aim to digitise their operations, BuddyCare is a mobile care coordination platform that automates patient pathway coordination. PATIENT EDUCATION - DATA COLLECTION - CARE COORDINATION - ANALYSIS Buddy Healthcare is on a mission to transform care coordination in hospitals and clinics by making care accessible and measurable for everyone, everywhere and anytime. BuddyCare App for Patients The BuddyCare App provides patients with all the information they need to navigate throughout the care process. It automates the workflow, communication, instructions, forms, and reminders so that patients are always aware of the next steps on the care path. The app is customised based on the care provider's needs so that it's always perfectly in-line with the patient processes and workflows. A white-label application is available with rapid delivery time for those care providers, who wish to have their own branded application. BuddyCare Dashboard for Care Personnel Through the BuddyCare Dashboard, care personnel has real-time visibility over patients’ preparation and recovery activities. The tool is used to collect, analyse and visualise patient data, which allows care personnel to focus on those patients most in need of attention. The system also uses data analytics to early predict risks for surgery no shows, and to find evidence-based best practices for patient pathways to improve the quality of care. Buddy Healthcare is a young Finland-originated company with a vision to transform pre and post-operative care. Visit our website https://www.buddyhealthcare.com/en/ or book a free online meeting with our expert.

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Our vision is to create a healthier everyday life for the many people. At Noös, we believe that if the company is an economic device serving a cause of production, it is above all a community of employees serving that cause. Our goal is to offer our clients solutions that will allow them to rethink the their community and collective values. To better protect their employees by reintroducing the values of kindness and compassion within their company.

CUREosity is a multiple international award-winning Med-Tec company located in Düsseldorf, Germany, that is changing rehabilitation by developing innovative therapy concepts. With our vision to revolutionize traditional rehabilitation we develop VR-based therapy applications and games to help people with neurological and mental disabilities. Change the world and become part of a unique collaboration between scientists, medical doctors, therapists, software developers and game designers. Together we develop completely new motion therapy systems - immersive instead of invasive. Impairments we aim to heal include stroke, craniocerebral trauma, MS, cerebral palsy, Parkinson's, paraplegia as well as dementia, depression, anxiety and pain therapy. With CUREO we developed our first smart software solution for innovative VR therapy that can be used immediately in any clinic. Grow with us! Give your daily work a deeper meaning and support us with your talent to help people with neurological and psychological disabilities. You can also benefit from being on board by growing with us personally and professionally, revolutionizing traditional rehabilitation. Became curious? Then follow or contact us on LinkedIn, visit our website and apply at jobs@cureosity.de!

CV6 Therapeutics is an early stage drug development company focused on the discovery, development and commercialization of novel combination therapies for the treatment of cancer. For further investment questions or opportunities please contact: information@cv6t.com

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d’Études et de Recherches pour l’Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Elsa Science strives to contribute to a future where chronic disease is minimized. Where people who are diagnosed can reach optimal health sooner and live a new life faster, and to its full potential. Elsa Science was established in 2017 by a team of influential scientists and award winning designers who have a passion to improve the health of people living with chronic disease. Driven by science, self-reported patient data, and individualized care, and through meaningful content and design, Elsa Science aims to make science accessible and put it in the hands of the people living with a chronic disease. Providing motivation and education through two tools - the Elsa Science Self-care app and Clinical Dashboard, bring patients and families closer together with healthcare providers through seamless data sharing. Our digital solution provides a powerful communication tool for a greater good, to better manage the illness, improve healthcare, and empower the individual to proactively self-care.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Cardiovascular Remote Patient Monitoring with pulsewave analysis - in the field of pregnancy, chronic cardiovascular diseases, lifestyle change and research.

Bereavement support for the modern world. With a combination of technology & human support, Empathy helps families through all the financial, legal, emotional, and logistical challenges that follow loss.

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Fitpuli is an expert of workplace wellbeing. We make workplaces healthier - and by that we save companies serious money. Because workplace wellbeing is not nice-to-have, it's must-have. Our principle is that we should consider health in the light of lifestyle and for that we offer a sustainable, scalable and measurable solution. Our main tools are: - Health Map for assessing the employees’ lifestyle - Fitpuli application for monitoring physical and mental health and lifestyle data - Health modules for building healthy habits - Teambuilding via community challenges Why does investing in workplace wellbeing worth it? - It’s quantifiable - Every effort made towards employee health and wellbeing symbolizes how valuable employees are for the company, and employees who feel valued are more content, more committed, more motivated and more productive. - Small and big companies are in the same race for recruiting the best employees, health benefits can be a huge advantage. - Workplace wellbeing programmes also help building a stronger community. Why Fitpuli? - The leaders of Fitpuli are health professionals, our health modules are built on scientific evidence. - Fitpuli app works on any smartphone, needs no special device, but works with basically every commercially available wearables. - Our community challenges and health modules require no professional equipment or preparation – this makes it easier to involve employees. - We offer different subscriptions for different needs, from occupation healthcare to a complete digital health programme or health insurance. Workplace wellbeing – physical and menta las well – is a value, let’s talk about it!

Flash Therapeutics is a World-class CDMO expert in lentiviral vector manufacturing : With our continuum from research to the clinic we support you throughout your projects from R&D to GMP grade. We provide purified and highly concentrated particles from small scale to large scale with the same vector specifications. Flash Therapeutics provides both integrative lentiviral vectors and non-integrative LentiFlash® particles. Lentiviral vectors : Conventional lentiviral vectors, which lead to DNA integrated into the genome, are a leading delivery method for applications which require a stable and long-term gene expression. Ideal for Gene Therapy and Immunotherapy. LentiFlash® particles : LentiFlash® combines a transient expression with a safe and efficient RNA delivery. This proprietary technology allows the delivery of multiple RNA species, without any genomic scar. Ideal for Regenerative Medicine, Gene Editing and Vaccination / Immunotherapy studies Contact us to design your project !

We’re a tech startup on a mission to bring accessible, affordable mental health support to everyone who needs it by empowering people to support each other. We do this by mobilizing and scaling peer support with tech. We are building a future of flourishing minds for all: where everyone can be their best self and achieve their potential, starting with college students.

kiweno empowers individuals to understand, manage and optimize their own health in a personalized and engaging way. By combining simple and affordable home-to-laboratory and rapid tests with interactive online data visualization, we provide unprecedented insights into one's health. This tailored information is displayed in a personal web-based health profile, enhanced by motivational features to help people reach their health goals easier, faster and with more joy.

At Koa Health, we’ve made it our mission to leverage technology and research to create simple, personal and accessible mental health support by combining evidence, cutting-edge tech and user-centered design. We create breakthrough interventions backed by science with one clear goal: to improve people’s mental health. We deliver effective, accessible mental health support that adapts to their unique circumstances. Our international team of behavioral scientists, developers, designers and health innovation leaders work, learn and grow together in a collaborative and inclusive culture. Want to learn more about life at Koa Health? Visit our website at koahealth.com

Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs. Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037

We develop diagnostics that are fast, accurate and can be used at the point of care: ensuring the first prescription, is always the right prescription. Our technologies answer 2 vital questions to ensure effective and sustainable use of antibiotics: Does the patient have an infection treatable with antibiotics? NANOPLEX® is an advanced latex agglutination test that can be used to rapidly identify and quantify the cause of infection in 5 minutes. What will be the most effective antibiotic treatment? SCFI™ is a phenotypic, real-time and growth-free antibiotic susceptibility test that determines the most effective antibiotic in 30 minutes.

Founda enables healthcare to collaborate and innovate by offering a platform that exchanges data between healthcare IT systems and external applications. We introduce platform thinking in healthcare by offering scalable infrastructure and reusable, standardised integrations with healthcare IT systems. Hospitals, medical practices, labs and others use our platform to collaborate and get easy access to the latest healthcare applications. We offer free integrations and companies only pay for actual use. Because of a dramatically lower barrier to entry, healthcare profits as a whole by opening the door for innovative solutions. See our website https://founda.com/ or send us an email at hello@founda.com

Founded by a powered wheelchair user, we create next-generation mobility products to allow wheelchair users to live the life they choose. The founder, Alex Papanikolaou, created Freedom One Life due to the limitations of the stagnant powerchair market which he experienced first-hand. Our vision is to deliver radical change to the market, offering a revolutionary powered wheelchair to improve independence and stretch the boundaries of powerchair users.

Frog Systems provides early support to help employees through life’s challenges. Ashia supports employees at an early stage – the first line. Proactive support will positively boost employee morale and purpose, and with it, retention, and company resilience. To learn more visit frogsystems.co.uk

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Created in 2001, Genoscreen provides genomic services and innovative solutions in genomics. Our offer addresses academic and industrial research teams which need to analyse DNA and explore its properties. The health, agrofood and environmental sectors are our main markets. The company’s portfolio includes: • Services in molecular biology analyses (DNA sequencing, genotyping, detection of gene mutation, metagenomics analysis in complex environment…) • Innovative kits to standardize and facilitate specific analyses (kit for microorganisms strains tracing, kit for identification of microbial community in all kinds of environment…) • Expertise and consultancy services for companies which develop projects in genomics GenoScreen also proposes custom-made trainings to people wishing to learn or improve their level about genomic analyses. GenoScreen collaborates to international research programs on Alzheimer’s disease, epidemiological surveillance of pathogens and biodiversity. Key figures: • 30 employees, doctors, engineers and technicians • 300 customers across the 5 continents • 35% of revenues coming from 30 countries outside France • 30% of revenues dedicated to R&D

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

GlowDx is developing the Worlds First True Point-of-Care (POC) Diagnostics Platform, aimed at tackling Infectious Disease in Emerging Economies. Our first test detects mosquito-bourne infections (Dengue Fever, Chikungunya & Zika Virus), while our AI utilizes machine learning to model & predict future outbreaks.

Gotocure is a marketplace focused on the experience of patients who want to purchase healthcare in a foreign country. Patients ask for offers from clinics according to their needs. In addition to clinic reservations, they can meet their needs such as flight tickets, hotels, city transportation. They can insure the risks that may occur during their travels. Gotocure has quality standards. Clinics, hotels, all business partners are determined according to these standards. Gotocure's end-to-end solution and service portfolio is both competitive and secure. We create lasting value for our customers through open collaboration with ecosystem partners. Thank you for visiting us and wish you a pleasant time on our page.

Gradientech is a Swedish biotech and diagnostics company dedicated to support the modern microbiology lab with state-of-the-art solutions to facilitate the workflow with time-critical samples. Our product QuickMIC® is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument module analysing one sample against multiple antibiotics, well-suited for small and larger clinical laboratories. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST on the market. Gradientech’s technology combines microfluidics with live cell imaging to study cell responses in a linear concentration gradient. Our technology is a perfect match for many biological applications. Gradientech holds an ISO13485 certification.

ianacare’s mission is to empower and equip working caregivers with tools, resources, and community. To truly build the infrastructure of support today’s family caregivers need, we are bringing together, perspectives, and resources from all corners of society through the I Am Not Alone Care Alliance. Together, we will shape policy, workplace norms, and create cultural change around how we care for one another. Learn more about our Alliance: https://ianacare.com/alliance/. We redefine the caregiving journey by connecting every layer of practical and emotional support for any caregiving situation. Our easy-to-use solution allows caregivers to manage caregiving responsibilities through private care teams, access fully integrated employee programs & benefits, review expert content and vetted services by zip code, and chat 1-1 with a team of specialized Caregiver Navigators. Our impact is real. Our white-glove concierge leverages the power of tech to make it global, equitable, and sustainable. We approach support through personalized data-driven care. We are a clinically proven solution that increases productivity by 83% and decreases stress and burden by 30%. ianacare users take less unplanned time off, experience improved mental health, and overall improved employee satisfaction. ianacare is headquartered in Boston, MA, and backed by Greycroft with participation from 8VC, SemperVirensVC, Able Partners, and Brown Alumni Group. Follow-on investments from existing investors include Founder Collective, Indicator Ventures, Entree Capital, Cue Ball, Service Provider Capital, and AARP. Contact: https://ianacare.com/employers/

Idoven is a health technology company advancing early detection and precision medicine for cardiovascular diseases. The Idoven AI-powered platform delivers substantial improvements to the speed, consistency and accuracy of electrocardiogram (ECG) interpretation. Its powerful, proprietary AI algorithms, which work with existing ECG devices, are also being applied to develop disease biomarkers towards patient identification, risk stratification and prognosis, as well as drug cardiac safety monitoring. Idoven partners with leading medical device and pharmaceutical companies on AI-driven innovations to develop a new standard of cardiovascular care. Through exclusive partnerships and research collaborations, Idoven has developed one of the world’s largest ECG databases and a deep learning system applied to cardiology. The Idoven software is designed to be integrated seamlessly into existing clinical and research workflows, to support clinician decision making and disease management. Idoven has been awarded with numerous distinctions for its AI technology in Europe and the US, including the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 (H2020) awards and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. The company is backed by top tier investors including Insight Partners, Northzone and Wayra (Telefónica), the Accel Starters programme, leading business angels and EIT Health. Idoven is based in Madrid and was founded in 2018, following almost a decade of ground-breaking research. We are building the future of cardiovascular care, and we need the best minds from around the world to help us. Interested in joining our team? Head to our careers page and apply at www.idoven.ai/jobs

Ifeel is the leading company in emotional well-being for modern organizations and insured employees. Founded in 2017, this holistic psychological support platform combines artificial intelligence with individual therapy carried out by our team of psychologists specialized in occupational health. Through our emotional support program for companies, we offer an all-in-one solution. HR managers will be able to support their employees' mental health through different levels and receive continuous and personalized advice to boost their psychological well-being whilst obtaining data on the status of their organization's working environment. We attend hundreds of thousands of patients every month in five different languages, in more than 30 countries, such as Spain, Portugal, France, Brazil, Mexico, and Colombia, among others. Large organizations such as Gympass, Glovo, and Axa Partners already rely on the leading emotional well-being program for their staff’s occupational health, which has led to a great improvement in productivity, performance, commitment, motivation, and work environment among their employees. Investing in the psychological health of your team guarantees a healthy company.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Our Vision: Our intelligent sensing platforms integrated on all plasma and RF processing equipment to enable atomic-scale engineering for the advancement of nano-technology. Our Mission: Creating intelligent sensing platforms for advanced plasma and RF manufacturing processes, to improve process performance and reduce product scrap. Our Purpose: Our company exists because we believe in the science of measurement. We believe that accurate process measurement is critical for the future of nano-scale manufacture, where process stability and repeatability are paramount to delivering the technology of the future. We measure parameters and processes under some of the most extreme environments encountered on earth. We measure things often considered impossible. #MeasuringTheImpossible. Our value proposition is that we provide you with an independent diagnosis of your process health, using intelligent, network-enabled sensing platforms, in conjunction with our vast experience in RF and plasma systems, to help you solve the most complex processing issues.

The health coaching revolution starts here Lenus partners with the world’s best health & fitness coaches to power their growth. We support the new generation in taking their coaching business to the next level. People who want to change the world. People who have the power to move not only bodies, but minds too. We empower coaches to be bold and boundless. And get limitless growth at their fingertips. Fusing together our innovative tech, strategic expertise & human connection, we’re fully equipped to handle the business of coaching, so that coaches can focus on delivering real value to their clients. We’re accelerating the holistic health revolution.

At Lifekeys, we're on a mission to change the workplace for the better with an all-in-one digital solution that broadens access to the best in evidence-based psychological support.

Livmed's is a software platform that provides home medicine delivery services for fellow citizens and healthcare players.

LiveMetric is a leader in continuous, wearable blood pressure monitoring for hypertension and cardiovascular disease. Through the development of proprietary sensor technologies coupled with AI insights, LiveMetric is the first cuffless, wearable, continuous BP monitor with accuracy highly correlated to the arterial line. And, is uniquely positioned as the only continuous monitor that does not require calibration and therefore can be implemented and sustained at home without ever having to visit to the providers office. The LiveMetric platform delivers hundreds of accurate BP measurements both day and night alongside heart rate, heart rate variability and steps taken. Providers will achieve real-time, personalized care and treatment for their patients through electronic transmission of the data to their medical records systems. The LiveMetric platform is part of a small, select group of blood pressure devices that are clinically validated for accuracy. Providers and users can rely on LiveMetric measurements the same as they would rely on arterial line measurements from the hospital. Through this level of accuracy our vision is to empower providers and patients with unparalleled data and actionable insights that will transform hypertension treatment and care resulting in better, healthier lives.

Our story began when Loop's founders, Maarten and Dimitri, had a common problem: ringing ears after a night out. They discovered that they were not alone, as 1 in 4 adults suffer from hearing damage. But why weren't they wearing earplugs? This question sparked the inception of Loop. At Loop, we are dedicated to revolutionizing the way earplugs look, feel, and sound. Whether you need hearing protection or simply want to ensure comfort for your ears, Loop allows you to live life at your own volume. Based in Antwerp with offices in Amsterdam, New York, and Shanghai, we are a rapidly growing team of almost 100 people. This year, we have tripled our sales and have sold over 2,5 million pairs of Loop earplugs worldwide. As winners of Deloitte Belgium's Technology Fast 50 Award 2022 , we are proud to be recognized as Belgium's leading tech scale-ups, paving the way for innovative brands in the country.

GoodGut is a biotechnology company focused on researching and developing analysis systems and therapeutic products to improve the diagnosis and treatment of digestive diseases based on intestinal microbiota. We aim to provide technological tools that will help to obtain a faster, more reliable and lower cost medical diagnosis than existing methods, alongside therapies to improve the quality of life of patients with compromised digestive health. The company was created in 2014 as a spin-off of the University of Girona (UdG) and the Institute of Biomedical Research of Girona Dr. Josep Trueta (IdIBGi). Our facilities can be found in the Scientific and Technologic Park of the UdG, an innovation hub housing over 140 companies, research groups and institutions.

Vision: Global leadership in MedTech innovation for India and Global Markets Mission: Creating the world’s first portfolio of medical products, designed, engineered, and priced for Global Markets InnAccel identifies critical, unmet, healthcare needs, using the Stanford Biodesign process, and works on selected clinical needs with large global markets. The selected needs are taken forward to develop a regulatory-certified, world-class, product, deploying InnAccel’s proprietary Product Engineering & Development (PED) platform, in 2 – 3 years. InnAccel’s portfolio comprises 3 novel products addressing a global market of >$10 billion, and addresses conditions that lead to almost a million deaths in India alone each year. InnAccel has over 30 professionals (engineers, designers, clinicians) at its Innovation Center, led by a team that brings together entrepreneurial, technology development, and clinical experience. Our strategic advisory board includes industry leaders, and we have a network of 50+ advisors/ mentors to guide project teams. InnAccel is focused on transforming healthcare and attaining global leadership in medical technology for emerging markets, by 2025.